Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocyte progenitor cells (225 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 5448
Sealed predictions
- OLFM2 in dopamine neurons, braak-0.45 (p 0.230) → -0.56 (p 0.114)receipt 5455
- OLFM2 in oligodendrocytes, braak-0.82 (p 0.007) → -0.11 (p 0.775)receipt 5454
Swarm cases
receipt 5455: OLFM2 in dopamine neurons, braak
- power
- full sample -0.31 (p 0.207, n 18), 95% CI -0.68 to +0.18. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.36 (p 0.142, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.41 (p 0.087, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.22, sign flips 0; without severely affected donors -0.31 (p 0.207, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for OLFM2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 5454: OLFM2 in oligodendrocytes, braak
- power
- full sample -0.40 (p 0.097, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.42 (p 0.080, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.66 (p 0.0026, n 18). not the mix.
- skeptic
- leave-one-out range -0.55 to -0.32, sign flips 0; without severely affected donors -0.40 (p 0.097, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for OLFM2 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts